tirzepatide surmount-1 nejm 2022 weight loss percent In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body and waist circumference. Full trial results and Research Summary Surmount Press Briefing #ADA2022
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3


























